Overview

Pazopanib Maintenance for SCLC

Status:
Completed
Trial end date:
2017-12-01
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy of pazopanib maintenance after 1st line CTx for SCLC.
Phase:
Phase 2
Details
Lead Sponsor:
Samsung Medical Center